NextCure Earnings Call Transcripts
Fiscal Year 2026
-
SIM0505, a CDH6-targeting ADC, showed a 55% response rate in heavily pretreated gynecologic cancers, with favorable safety and low ILD risk. Dose optimization is ongoing, and the drug may address significant unmet needs in ovarian and uterine serous carcinoma.
Fiscal Year 2025
-
Lead ADC programs SIM0505 and LNCB74 are progressing in phase I, with data expected in the first half of next year. The company is well-funded into 2027, plans further financing for phase II, and is spinning out non-oncology assets to maintain ADC focus.
-
Two ADCs targeting gynecological and other tumors are in phase one, with unique constructs and patient selection strategies aiming for superior efficacy and safety. Key proof-of-concept data for both assets are expected in the first half of next year, supported by strong partnerships and financial resources.
-
LNCB74, a B7H4-targeted ADC, is in phase I for women's cancers, leveraging a stable glucuronidase linker for improved safety and efficacy. Clinical proof of concept is expected in early 2026, with a strong financial runway and active partnering for additional pipeline assets.
Fiscal Year 2024
-
IND filed for LNCB74, a novel ADC targeting B7-H4 in women's cancers, with phase 1 trials set to begin. Strategic partnerships are advancing other assets, including NC410, NC605, and NC181, while a $75M cash position funds operations into 2026.
-
A novel antibody, NC-181, targeting APOE4 for Alzheimer's, demonstrated reduced amyloid pathology and improved vascular safety in preclinical models. IND filing is planned for 2025, with Phase I trials to focus on safety, PK, and biomarker development.